Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Summary

The purpose of this study is to look at the effects of cabozantinib on castrate-resistant prostate cancer metastatic (cancer that has spread to other parts of the body) to the bone and to learn about any side effects caused by taking cabozantinib.

Timeline

Start

2012-02

Primary completion

2014-10

Completion

2015-09

Outcome

Outcome not reported

Stopped (Enrollment): “Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.”

Drugs

Indications